Folfox4 adjuvant chemotherapy after curative resection of small hepatocellular carcinoma

Abstract

Objective To compare the recurrence and survival rate between small hepatocellular carcinoma (HCC)patients with and without folfox4 adjuvant chemotherapy after radical resection. Methods From April 2006 to October 2012 46 HCC cases after curative resection received folfox4 adjuvant chemotherapy, 51 cases served as control. Results The clinical and pathological data of the two groups were not significantly different. The 1, 2, 3, 4, 5 -year disease-free survival of the group with folfox4 adjuvant chemotherapy was 89%, 70%, 59%, 48%, 35%, and that was 78%, 65%, 53%, 37%, 27% in control group, the difference was not statistically significant (P=0.459). The 1, 2, 3, 4, 5-year overall survival rate of the group with folfox4 adjuvant chemotherapy was 96%, 76%, 63%, 57%, 52%, that in control group was 96%, 73%, 59%, 51%, 47%, the difference was not statistically significant (P=0.459). COX -hazards regression showed folfox4 adjuvant chemotherapy was not independent factors of recurrence and prognosis (P= 0.467, P=0.834). Conclusions For patients with hepatocellular carcinoma smaller than 5 cm in diameter, folfox4 adjuvant chemotherapy after radical resection did not reduce the recurrence rate and did not improve survival. Key words: Carcinoma, hepatocellular; Hepatectomy; Chemotherapy, adjuvant